Dr Jabbour on the Efficacy of Ponatinib in Newly Diagnosed P

Elias Jabbour, MD, discusses efficacy data from the phase 3 PhALLCON trial of ponatinib plus reduced-intensity chemotherapy vs imatinib plus reduced-intensity chemotherapy in newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Related Keywords

Texas , United States , Philadelphia , Pennsylvania , Elias Jabbour , Division Of Cancer Medicine , Department Of Leukemia , University Of Texas Md Anderson Cancer Center , Cancer Medicine , Cancer Center , Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia , Bph , Wall , Imatinib , Ponatinib , Phallcon , Eha Congress ,